Avalo Therapeutics

View the org chart displaying its 9 main executives

Most searched biographies at Avalo Therapeutics

• Garry Neil, Chairman of the Board and Chief Executive Officer
• Magnus Persson, Lead Independent Director
• Mitchell Chan, Director

Create your alert
to follow the executive moves at Avalo Therapeutics.

Avalo Therapeutics has 2,182 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Biogen (United States (USA)).

Popular M&A news in Biotechnology

• Carmot Therapeutics has just announced a $150 Million fundraising (posted on June 1 2023).
• BenchSci has just announced a $70 Million fundraising (posted on May 30 2023).
• ElevateBio has just announced a $401 Million fundraising (posted on May 26 2023).

Popular contacts in Biotechnology

• Neal Mohan - Director at 23andMe
• Marc Dunoyer - Independent Director at Orchard Therapeutics
• Kelly Liebman - Senior Vice President of Sales at Rightway Healthcare

Learn more about the Biotechnology industry >

Press releases by Avalo Therapeutics

• Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board :: Avalo Therapeutics, Inc. (AVTX)
• Avalo to Present at ATS 2023 Respiratory Innovation Summit :: Avalo Therapeutics, Inc. (AVTX)
• Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Reports 2022 Financial Results and Provides Business Updates :: Avalo Therapeutics, Inc. (AVTX)
• Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million :: Avalo Therapeutics, Inc. (AVTX)
• View more press releases Close

Social media about Avalo Therapeutics

• Avalo Therapeutics on Wikipedia, Google News & Yahoo Finance
• Avalo Therapeutics on LinkedIn, Twitter & YouTube

Contact by email its executives including Garry Neil

Call Avalo Therapeutics at +1 610...

View the org chart

Register to receive your alert

Report an error